Physician profile
James D Vanwinkle
NPI 1720269616
$312.49
in general payments reported to CMS, 2019-2025
13 companies · $40.50 in 2025
The $40.50 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.92 · 2020: $13.70 · 2021: $74.92 · 2022: $85.87 · 2023: $42.35 · 2024: $40.23 · 2025: $40.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $43.67 | 2021-2022 | |
| Abbvie INC. | $39.89 | 2021 | |
| Olympus America INC. | $30.62 | 2019-2022 | |
| Boston Scientific Corporation | $27.26 | 2020-2023 | Spyglass |
| Braintree Laboratories, INC. | $26.80 | 2022-2023 | Suflave |
| Lundbeck LLC | $21.50 | 2024 | Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.13 | 2025 | Caplyta |
| Lilly USA, LLC | $19.37 | 2025 | Mounjaro, Zepbound |
| Reprise Biomedical, INC. | $19.02 | 2022 | |
| Medtronic, INC. | $18.73 | 2024 | Endurant Iis |
| Teleflex LLC | $17.20 | 2021 | |
| Lucid Diagnostics INC. | $14.97 | 2023 | |
| Innocoll Pharmaceuticals Limited | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Vanwinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.